Application of Nanomedicine in Metabolic and Chronic Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 30 December 2024 | Viewed by 65
Special Issue Editor
Special Issue Information
Dear Colleagues,
Metabolic and chronic diseases pose a significant global health burden, necessitating innovative therapeutic strategies. In recent years, the application of nanotechnology in the field of medicine has emerged as a promising approach for addressing the challenges associated with metabolic and chronic diseases. Nanomedicine offers a unique opportunity to target specific molecular pathways, improve drug delivery, and enhance therapeutic outcomes. This Special Issue aims to explore the latest advancements in nanomedicine for treating and managing metabolic and chronic diseases. It will cover topics such as nanoscale drug delivery systems and nanotheranostics, focusing on their application in treating metabolic disorders, such as diabetes, and chronic conditions like cardiovascular diseases. It will span from the design and development of nanomedicine formulations to preclinical and clinical evaluations.
This Special Issue invites researchers and clinicians to contribute their latest findings, including original research articles and reviews, fostering a comprehensive understanding of nanomedicine's role in revolutionizing chronic disease management.
Dr. Mehrnaz Abbasi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- metabolic diseases
- chronic diseases
- drug delivery
- nanoscale materials
- targeted therapy
- controlled release
